Evidence map›Paper›PMID 34295724›Full record

ArticleTranslational andrology and urology2021

Britta Grüne, Jan Rother, Frank Waldbillig, Ganapathy Chellappan, Sabine Meessen, Bartłomiej Grychtol, Nikolaos C Deliolanis, Christian Bolenz, Maximilian C Kriegmair

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Britta GrüneDepartment of Urology and Uro-Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Jan RotherMedical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Frank WaldbilligDepartment of Urology and Uro-Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Ganapathy ChellappanMedical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Sabine MeessenDepartment of Urology, University of Ulm, Ulm, Germany.
Bartłomiej GrychtolMedical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Nikolaos C DeliolanisMedical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Christian BolenzDepartment of Urology, University of Ulm, Ulm, Germany.
Maximilian C KriegmairDepartment of Urology and Uro-Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Heidelberg University · DEUniversität Ulm · DEUniversity Hospital Heidelberg · DEFraunhofer Institute for Manufacturing Engineering and Automation · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-time multispectral imaging (rMSI) simultaneously provides white light (WL), photodynamic diagnosis (PDD) images, and a real-time fusion of both. It may improve the detection of bladder tumors. However, rMSI has not been used for transurethral biopsy or resection so far. The aim of this

methodsA 3D printed rigid bladder phantom was equipped with small and flat (5 mm × 1 mm) mock-bladder-tumors made of silicone and fluorescent Qdots655 (Thermo Fisher Scientific, Germany). Urologists (n=15) were asked to perform a rigid cystoscopy and biopsy of all identified lesions (n=6) using a prototype rMSI system and the Image1 S system (Karl Storz, Tuttlingen). Success rate and completion time were measured. The image quality of both systems and the usability of the rMSI system according to the system usability scale (SUS) were evaluated with a task-specific questionnaire.

resultsTumor detection and biopsy rate were 100% (90/90) for the rMSI system and 98.9% (89/90) for the Image1 S system (P=0.3). The biopsy completion time did not differ significantly between the systems (P=0.48). Differentiation between healthy and suspect mucosa with the rMSI system was rated as comparable to the Image1 S system by 53% of surgeons and as better by 33% of the surgeons. The median SUS score for the rMSI system was 87.5%.

conclusionsAccurate transurethral biopsies are feasible with the rMSI system. Furthermore, the rMSI system has an excellent SUS. This study paves the way to the first in-human transurethral resections of bladder tumors (TUR-B) using rMSI technology.

Indexed as

Bladder cancercystoscopymultiparametric cystoscopy (MP cystoscopy)multispectralphotodynamic diagnostic (PDD)

Identifiers

PMID34295724
PMCPMC8261439
OpenAlexW3162069495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.